AllDocs -> cancers

Review A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma Richard D. Riley, 1 David Heney, 2 David R. Jones, 1 Alex J. Sutton, 1 Paul C. Lambert, 1 Keith R. Abrams, 1 Bridget Young, 3 Alan J. Wailoo, 4 and Susan A. Burchill 5 Departments of 1 Health Sciences, 2 Medical Education, University of Leicester, Leicester; 3 Department of Psychology, University of Hull, Hull; 4 School of Health and Related Research, University of Sheffield, Sheffield; and 5 Cancer Research United Kingdom Clinical Centre, St. James’s University Hospital, Leeds, United Kingdom Abstract Purpose: The aim of this ...

Abstract. Background: The dietary carotenoid zeaxanthin protects against age-related eye disease by preventing apoptosis in photoreceptor cells. This study examined the effect of zeaxanthin on neuroblastoma cells in which apoptosis can be induced with lipid peroxidation products. Since zeaxanthin can inhibit lipid peroxidation and ‚-carotene inhibits lipoxygenase (LOX) activity, it was of concern that zeaxanthin might inhibit apoptosis in these cancer cells. Materials and Methods: Apoptosis-resistant CHP100 neuroblastoma cells were treated with zeaxanthin. Apoptosis was assessed via an immunoassay for histone-associated DNA fragments and cytofluorimetric analysis of apoptotic body formation. The effect of zeaxanthin on the activity of two model LOXs and LOX-mediated lipid peroxidation in liposomes was assessed. Results: Zeaxanthin strongly induced apoptosis ...

Survival of children with neuroblastoma : time trends and regional di?erences in Europe, 1978±1992 C. Spix a, *, T. Aareleid b,c , C. Stiller d , C. Magnani e , P. Kaatsch a , J. Michaelis a a Institute for Medical Statistics and Documentation, German Childhood Cancer Registry, University Mainz, 55101 Mainz, Germany b Department of Epidemiology and Biostatistics, Institute of Experimental and Clinical Medicine, Tallinn, Estonia c Estonian Cancer Registry, Estonian Cancer Centre, Tallinn, Estonia d National Registry of Childhood Tumours, Childhood Cancer Research Group, Oxford, UK e Childhood Cancer Registry of Piedmont. Regional Centre for Cancer Epidemiology and Prevention in Piedmont. Turin, Italy Received 27 September 2000; accepted 27 December 2000 ...

Neuroblastoma Neuroblastoma Morning Report Morning Report October 12, 2005 October 12, 2005 Page 2 Epidemiology Epidemiology Most common Most common extracranial extracranial solid tumor of solid tumor of childhood childhood Third most common childhood cancer, after Third most common childhood cancer, after leukemia and brain tumors leukemia and brain tumors Most Most common cancer in infants < 12 months common cancer in infants < 12 months Incidence is 1:10,000 Incidence is 1:10,000 Median age of diagnosis is 22 months Median age of diagnosis is 22 months 85% of cases diagnosed before age 5 85% of cases diagnosed before age 5 40% of cases diagnosed before age 1 40% of cases diagnosed ...

Receptors and Channels , 9: 387–396, 2003 Copyright c Taylor & Francis Inc. ISSN: 1060-6823 print / 1543-5334 online DOI: 10.1080/10606820390257533 Biophysical Properties of Kv3.1 Channels in SH-SY5Y Human Neuroblastoma Cells P. Friederich Universitatsklinik fur Anasthesiologie, University of Hamburg, Hamburg, FRG J. P. Dilger Departments of Anesthesiology and Physiology and Biophysics, University at Stony Brook, Stony Brook, New York, USA D. Isbrandt, K. Sauter, and O. Pongs Institut fur Neurale Signalverarbeitung, Zentrum fur Molekulare Neurobiologie, University of Hamburg, Hamburg, FRG B. W. Urban Klinik fur Anasthesiologie und spezielle Intensivmedizin, University of Bonn, Bonn, FRG, and Departments of Anesthesiology and Physiology, Weill Medical College of Cornell University, New York, New York, USA ...

MEDIA RELEASE April, 2005 New development in fight against childhood cancer Researchers at the Flinders Medical Centre have discovered a way to ‘switch off’ drug resistant genes to increase the chances of survival among children diagnosed with blood- related cancers. The research team, lead by Dr Bryone Kuss from the Department of Haematology and Genetic Pathology, has explored the role of certain drug resistant genes in neuroblastoma tumour cells and is investigating new approaches for the treatment of both neuroblastoma and acute leukemia. “It is not uncommon for cancers to become resistant to chemotherapy or radiotherapy and ultimately lead to cancer relapse,” Dr Kuss said. The team’s aim is to understand the mechanism behind the resistance in the cancers, which predominately affect children from birth. Although cure of acute leukemia is achievable in approximately ...